Insider Trading Alert - RTEC, PFE And AMRI Traded By Insiders
at The Street - Fri Feb 13, 10:30AM CST
Stocks with insider trader activity include RTEC, PFE and AMRI
PFE: 34.64 (-0.23), RTEC: 12.14 (-0.17), AMRI: 16.94 (-0.28)
AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers
PR Newswire Europe - Thu Feb 12, 3:01PM CST
-- Announces Key Leadership Promotions
AMRI: 16.94 (-0.28)
Albany Molecular Research's (AMRI) CEO Bill Marth on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 1:43PM CST
AMRI: 16.94 (-0.28)
Albany Molecular Research (AMRI) Q3 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:25AM CST
AMRI: 16.94 (-0.28)
Albany Molecular Research posts 4Q loss
Automated Insights - Thu Feb 12, 7:07AM CST
ALBANY, N.Y. (AP) _ Albany Molecular Research Inc. (AMRI) on Thursday reported a fourth-quarter loss of $1.9 million, after reporting a profit in the same period a year earlier.
AMRI: 16.94 (-0.28)
Albany Molecular misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:54AM CST
AMRI: 16.94 (-0.28)
AMRI Announces Fourth Quarter and Full Year 2014 Results
PR Newswire Europe - Thu Feb 12, 6:31AM CST
-- Fourth quarter contract revenue of $80.7 million, up 35% from 2013
AMRI: 16.94 (-0.28)
AMRI Announces Proposal to Close UK-Based API Manufacturing Facility
PR Newswire Europe - Thu Feb 12, 6:31AM CST
AMRI announced today its intention, subject to consultation with its UK workforce, to close its UK facility in Holywell, Wales, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API).
AMRI: 16.94 (-0.28)
5 Hated Earnings Stocks That You Should Love: Pinnacle Entertainment and More
at The Street - Tue Feb 10, 8:02AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
PNK: 25.64 (-0.35), KN: 18.59 (-3.05), CSOD: 35.03 (+2.02), BCOR: 14.20 (-0.45), AMRI: 16.94 (-0.28)
AMRI Hires Chief Information Officer
PR Newswire Europe - Mon Feb 09, 3:00PM CST
AMRI announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.
AMRI: 16.94 (-0.28)
Analysts View on Health Care Sector Equities -- GlaxoSmithKline, Novartis, Illumina, PerkinElmer, and Albany Molecular Research
PR Newswire - Thu Feb 05, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Novartis AG (NYSE: NVS), Illumina Inc. (NASDAQ: ILMN), PerkinElmer Inc. (NYSE: PKI), and Albany Molecular Research Inc. (NASDAQ: AMRI). Free research report on GlaxoSmithKline can be accessed at http://get.Investor-Edge.com/pdf/?c=GlaxoSmit...&s=GSK. On Wednesday, February 04, 2015, the NASDAQ Composite ended at 4,716.70, down 0.23%, the Dow Jones Industrial Average advanced 0.04%, to finish the day at 17,673.02, and the S&P 500 closed at 2,041.51, down 0.42%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, while the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
ILMN: 198.54 (+1.81), GSK: 47.94 (+1.99), AMRI: 16.94 (-0.28), PKI: 46.30 (-0.10), NVS: 102.20 (-0.17)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
AMRI to Announce Fourth Quarter and Full Year Results
PR Newswire - Thu Jan 29, 7:00AM CST
AMRI (NASDAQ: AMRI) today announced it will issue fourth quarter and full year financial results before the opening of the market on Thursday, February 12, 2015. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 16.94 (-0.28)
Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product
PR Newswire Europe - Mon Jan 26, 3:01AM CST
OXFORD, England, January 26, 2015 /PRNewswire/ --
AMRI: 16.94 (-0.28)
AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and Clinical Drug Product
PR Newswire Europe - Mon Jan 19, 7:01AM CST
- 10-year Federal Contract Award Valued at up to $37 Million -
AMRI: 16.94 (-0.28)
New finance chief at AMRI
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 3:53PM CST
AMRI: 16.94 (-0.28)